Metropolis Healthcare FY26 PAT ₹145 Cr; Declares ₹1 Dividend

Metropolis Healthcare posted consolidated profit after tax of ₹144.97 crore on revenues of ₹1645.85 crore for the fiscal year ended March 31, 2026.
The company's Board of Directors has approved a second interim dividend of ₹1 per equity share for FY2025-26.

Reader Takeaway: Profit grew 7% to ₹145 Cr; ₹1 dividend declared; auditor change is key.

What just happened (today’s filing)

The Board of Directors of Metropolis Healthcare Ltd convened on May 13, 2026, to approve the audited standalone and consolidated financial results for FY2025-26.

The company reported standalone revenue of ₹1381.80 crore and profit after tax of ₹124.34 crore.

On the consolidated front, revenue stood at ₹1645.85 crore with a profit after tax of ₹144.97 crore.

A second interim dividend of ₹1 per equity share for FY2025-26 was declared, with May 19, 2026, set as the record date.

Furthermore, the Board appointed Deloitte Haskins & Sells Chartered Accountants LLP as the new statutory auditors for a five-year term, effective post the 26th AGM.

Dr. Nilesh Shah, President - Internal Assurance, will transition to an advisory role effective May 14, 2026.

Why this matters

The reported financial results indicate the company's performance over the fiscal year, providing a snapshot of its revenue generation and profitability.

The declaration of an interim dividend directly benefits shareholders, returning a portion of the company's earnings.

The appointment of a new statutory auditor like Deloitte signifies a fresh perspective on financial oversight and compliance.

Dr. Shah's transition to an advisory capacity suggests a planned succession and continuity in senior management roles.

The backstory (grounded)

Metropolis Healthcare is a significant diagnostics provider in India, known for its extensive network of labs and services.

The company has demonstrated a consistent approach to rewarding shareholders, with a history of interim dividend payouts.

In the previous fiscal year, FY2024-25, Metropolis Healthcare reported consolidated profit after tax of approximately ₹135.3 crore, indicating a year-on-year growth in profitability for FY2025-26.

What changes now

Shareholders will receive a ₹1 per equity share interim dividend.

Deloitte Haskins & Sells will undertake the statutory audit of the company's financial statements for the next five years.

Dr. Nilesh Shah's role will shift from day-to-day operations to strategic guidance in an advisory capacity.

Risks to watch

No specific risks were highlighted in the provided filing text or identified in initial grounded research concerning governance or regulatory issues for this announcement.

Peer comparison

Metropolis Healthcare's FY26 consolidated PAT of ₹144.97 crore is smaller than peers like Dr. Lal PathLabs (approx. ₹350 crore) and Vijaya Diagnostic Centre (approx. ₹250 crore).

However, the company remains a key player in the Indian diagnostic services sector, competing on network reach and service breadth.

Context metrics (time-bound)

• Consolidated revenue for FY2025-2026 was ₹1645.85 crore.
• Consolidated profit after tax for FY2025-2026 was ₹144.97 crore.
• Standalone revenue for FY2025-2026 was ₹1381.80 crore.
• Standalone profit after tax for FY2025-2026 was ₹124.34 crore.
• A second interim dividend of ₹1 per equity share was declared for FY2025-2026.

What to track next

Shareholders' approval at the upcoming 26th Annual General Meeting for the appointment of Deloitte Haskins & Sells.

Confirmation of the dividend payment within 30 days of its declaration.

Observing the operational adjustments and strategic input from Dr. Nilesh Shah in his new advisory role.

Monitoring the company's performance in the upcoming quarters against its peers.